1. Home
  2. SACH vs SCLX Comparison

SACH vs SCLX Comparison

Compare SACH & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

N/A

Current Price

$0.91

Market Cap

38.4M

Sector

Real Estate

ML Signal

N/A

Logo Scilex Holding Company

SCLX

Scilex Holding Company

N/A

Current Price

$4.41

Market Cap

34.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SACH
SCLX
Founded
2010
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.4M
34.4M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
SACH
SCLX
Price
$0.91
$4.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 165.1K
25.6K
Earning Date
11-04-2026
11-13-2026
Dividend Yield
★ 21.74%
N/A
EPS Growth
★ 104.30
N/A
EPS
★ N/A
N/A
Revenue
★ $57,500,000.00
$30,253,000.00
Revenue This Year
$94.91
$118.16
Revenue Next Year
N/A
$186.31
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.76
$4.20
52 Week High
$1.45
$27.00

Technical Indicators

Market Signals
Indicator
SACH
SCLX
Relative Strength Index (RSI) 52.63 31.54
Support Level $0.91 $4.20
Resistance Level $0.99 $5.60
Average True Range (ATR) 0.03 0.32
MACD -0.01 -0.02
Stochastic Oscillator 19.82 10.66

Price Performance

Historical Comparison
SACH
SCLX

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: